Abstract-Eight Na-repleted volunteers underwent 3 separate 90-minute infusions of either N G -nitro-L-arginine methyl ester (L-NAME) 3.0 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 or endothelin-A receptor (ET-A) blocker BQ-123 (BQ) 0.125 nmol ⅐ kg Ϫ1 ⅐ min
I
t is now well established that endothelium-derived nitric oxide (NO) plays a major role in the physiological maintenance of baseline systemic and renal circulation. 1 When tonic NO production is acutely abrogated by NO synthase inhibition (NOSI) in animals and humans, vasoconstriction takes place, with a dose-dependent increase in mean arterial pressure (MAP) and vascular resistance in many organs, including renal circulation. [1] [2] [3] In human kidney, we and others [3] [4] [5] have previously shown that NOSI with low-rate systemic infusion of N G -monomethyl-L-arginine (L-NMMA) or N G -nitro-L-arginine methyl ester (L-NAME) may reduce effective renal plasma flow (ERPF), renal blood flow (RBF), glomerular filtration rate (GFR), and Na excretion independently of any apparent change in MAP. Both withdrawal of tonic NO production and amplification of underlying endogenous vasoconstrictor systems, such as angiotensin II (Ang II) and sympathetic nervous system, may participate, at least under certain experimental conditions, in renal vasoconstriction secondary to NOSI. 1 In addition to NO (and prostacyclin), the 21-amino acid peptide endothelin (ET) is of special importance in endothelium-mediated hemodynamic regulation. 6 As an autocrineparacrine substance, ET is known to exert a potent, vasoconstrictive action in both systemic and renal vasculature. 7 Interactions between ET and NO are well known, including potentiation of ET-induced vasoconstriction and elevation in MAP 1, 6, 8 and enhancement of synthesis and release of ET after acute NOSI. 9 Vasoactive properties of ET are mediated by 2 receptor subtypes, ET A and ET B . 6 Both ET A and ET B in vascular smooth muscle cells seem to mediate vasoconstriction, whereas activation of ET B receptors in endothelial cells may cause vasodilation through the release of prostacyclin and NO. 6 However, local ET B blockade in the human forearm predominantly produces vasoconstriction, which suggests a prevalent, net vasodilatory NO-mediated effect of ET B receptors. 10 In both normotensive 10 and hypertensive humans, 11 forearm ET A blockade results in vasodilation that is almost completely inhibited by concomitant NOSI. 10 At the kidney level, studies in dogs and humans indicate the ET A receptor as the main mediator of the vasoconstrictor effect of ET, on the basis of the demonstrated capacity of selective ET A blockade to either produce renal vasodilation 12 or to abrogate renal vasoconstriction due to exogenous ET-1 infusion. 13 Until now, no studies have been conducted in humans on the relationship between tonic, NO-dependent regulation of renal hemodynamics and endogenous ET. Therefore, in view of the unequivocal importance of ET A receptors in both systemic 10, 11 and kidney 13 circulation of humans, we designed the present study to investigate whether activation of ET A receptors by endogenous ET contributes to the renal effects of acute NOSI. For this purpose, healthy, Na-repleted humans underwent infusion of L-NAME alone or in combination with the ET A receptor blocker BQ-123.
Materials and Methods

Subjects
Eight healthy subjects (3 men and 5 women), chosen from among the medical staff of Patologia Medica and Semeiotica Medica Institutes at the University of Parma and who provided written informed consent, participated in the study, which was conducted according to the ethical protocols of our institution. All the subjects were aged Ͻ40 years; had no evidence or history of disease of heart, liver, kidneys, or endocrine organs; had not abused alcohol or drugs; and were not currently undergoing medical treatment. Before the study, all subjects had a clinical examination, blood pressure measurement, ECG, and laboratory screening. Clinical data and laboratory results are given in Table 1 .
Experimental Procedure
In a randomized order, each subject underwent 3 infusion studies, the first with BQ-123 alone, the second with L-NAME alone, and the third with both drugs. In women, experiments were performed around the midpoint of the menstrual cycle. Before each experiment, subjects were maintained for 5 days on a controlled diet that provided 250 mmol/L Na, 80 mmol/L K, and 1800 to 2400 kcal per day.
At 10 PM of the day before the study, each subject received 8 mmol/L Li as carbonate salt, the exogenous Li being used as an approximate marker of proximal tubular reabsorption. 3, 14 After an overnight fast, infusion experiments were initiated at 8 AM. After a blood sample was drawn for the control of paraaminohippuric acid (PAH) and inulin measurement and hematocrit, a plastic indwelling catheter was placed into a cubital vein and a priming dose of inulin (Inutest 25% solution; 3000 mg/1.73 m 2 body surface area) and PAH (20% solution) (600 mg/1.73 m 2 body surface area) was injected. Then, an infusion of PAH and inulin in saline solution was initiated with a 50-mL syringe precision pump (Perfusion Secura, Braun Melsungen) at a rate adjusted to obtain plasma levels of Ϸ1.5 mg/dL for PAH and 20 mg/dL for inulin. The infusion continued throughout the entire study, which was performed with the subjects in a sitting position. A second indwelling catheter for blood sampling was immediately placed in the other arm and kept patent by constant pump infusion of 1.0 mL/h of saline solution.
After 60 minutes of equilibration (Ϫ45 minutes time), subjects emptied their bladders, then a 45-minute baseline clearance period was initiated. After 45 minutes, subjects again voided their bladders, then a pump infusion of either 0.125 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 BQ-123 or 3.0 g ⅐ kg Ϫ1 ⅐ min Ϫ1 of L-NAME in saline solution or both drugs, respectively, was initiated and maintained until the end of the study. Two additional 45-minute clearance periods were performed (0 to 45 minutes [P1] and 45 to 90 minutes ]P2]), then the experiment was stopped. A 300-mL tap-water load was administered hourly throughout the study to ensure an appropriate urine flow. Blood pressure was measured every 5 minutes with an automatic oscillometric monitoring device (TM 2421, A and D Co Ltd). Samples from urine volume excreted during each clearance period were taken for Na, Li, and NO 2 plus NO 3 (NO x ).
Samples for plasma PAH and inulin were drawn every 15 minutes during the entire study. Samples for plasma Na and Li were taken at Ϫ45, 0, ϩ45, and ϩ90 minutes.
Calculations
A satisfactory steady state of plasma concentration of PAH and inulin was obtained with our infusion technique. The variability in plasma PAH and inulin measured throughout infusion was of the same order of magnitude as the coefficient of variability found in duplicate analysis of single plasma samples (2.4% for PAH and 3.6% for inulin). Thus, we calculated ERPF and GFR without measuring urinary PAH and inulin. For this purpose, PAH and inulin were measured in the infusate, and we calculated infusion rates by multiplying their concentrations for the volume of infused solution per minute. By dividing the infusion rate for each measured plasma concentration, we obtained 4 values in the baseline period and 3 in each drug period for both ERPF and GFR. The mean values were used in the expression of data for each clearance period. We calculated filtration fraction (FF) by dividing GFR for ERPF, RBF by dividing ERPF for (1Ϫhematocrit), and renal vascular resistances (RVR) from MAP and RBF. Clearances of Li (CLi) and Na (CNa) were calculated with the mean plasma value for each period. Baseline plasma Li ranged from 0.10 to 0.18 mmol/L. We obtained values for the fractional excretion of Li and Na (FELi and FENa) by dividing CNa and CLi for GFR.
Study Drugs
PAH (20% solution) was purchased from J. Monico and Inutest from Laevosan Gesellschaft. Pharmaceutical grade L-NAME and BQ-123 were obtained from Clinalfa.
Analytical Methods
Na was measured by flame photometry and Li by atomic absorption spectrophotometry. Plasma and infusate PAH and inulin and urinary NO x were measured as described previously. 3, 14 
Statistical Methods
Data are expressed as the meanϮSEM. ANOVA and paired Student t test were used to compare the results obtained in different study periods in the same experiment and those of the same study period among the 3 experiments.
Results
No adverse effect due to BQ-123 or L-NAME administration was observed. Table 2 summarizes the results of our experiments for MAP and renal hemodynamics. Whereas BQ-123 alone did not exert any effect, L-NAME alone was followed by a slight but significant rise in MAP after only 45 minutes of infusion (ϩ7% from baseline, PϽ0.001 versus both baseline and BQ-123 alone). Renal hemodynamics were widely altered by L-NAME even at 0 to 45 minutes (P1), when MAP was unchanged. In that period, GFR diminished by Ϸ5% 
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(PϽ0.001 versus both baseline and BQ-123 alone), ERPF declined by 12.2% (PϽ0.005), and RVR increased by 14% (PϽ0.001). All these changes were more pronounced in P2, when ERPF and RBF were 18.3% lower and RVR was 31.4% higher than that calculated at baseline. With L-NAME plus BQ-123, changes in MAP in P2 were markedly blunted (ϩ2%; not significant versus baseline, PϽ0.005 versus L-NAME), whereas those in ERPF, RBF, and RVR were all significantly smaller than those with L-NAME in both P1 and P2. In particular, in P1, ERPF and RBF decreased by only 4.6% (PϽ0.005 versus baseline, PϽ0.05 versus L-NAME) and RVR increased by 5.6% (PϽ0.01 versus baseline, PϽ0.005 versus L-NAME). In P2, ERPF and RBF were diminished with respect to both baseline and BQ-123 (PϽ0.001), but they were less reduced than with L-NAME (PϽ0.02), whereas RVR was only 10% higher than at baseline (PϽ0.001 versus L-NAME). Conversely, GFR, although it showed a trend toward a smaller decrease than with L-NAME, was not significantly different between L-NAME and L-NAME plus BQ-123. FF, which showed a modest but significant increase in P2 with L-NAME (11%), did not change during infusion of L-NAME plus BQ-123 (PϽ0.005 versus L-NAME). In the Figure, the results obtained for MAP, GFR, RBF, and RVR are summarized in a graph form.
In Table 3 , we report the effects of infusion experiments on renal handling of Li and Na and excretion rate of NO x (UNO x V). BQ-123 did not produce any significant variation in baseline Li, Na, and NO x excretion. Infusion of L-NAME alone elicited a progressive decline in both absolute and fractional excretion of Li and Na, with values of UNaV, FENa, CLi, and FELi significantly lower in P2 than in P1. These changes in Na and Li handling were not modified by the combined infusion of L-NAME and BQ, which produced decrements in UNO x V comparable to those observed with L-NAME alone.
Discussion
The aim of the present study was to investigate whether interactions between tonic NO production and endogenous ET play a physiological role in the maintenance of baseline vascular tone in human kidney. To this purpose, renal hemodynamic changes after acute NOSI were measured with and without simultaneous blockade of ET at the level of ET A receptors.
In our experiments, NOSI was obtained with a low-rate, systemic L-NAME infusion technique. 3, 5, 14 Previous animal studies have shown that a simultaneous rise in renal perfusion pressure (RPP) by itself may be responsible for a consider- able portion of renal hemodynamic responses to acute systemic NOSI, including a marked rise in both afferent and efferent arteriolar tone with consequent elevation in FF. 8, 15, 16 Conversely, local intrarenal NOSI leads to smaller, although still substantial, increases in afferent tone and, to a lesser extent, in efferent tone. 8, 15, 16 In addition, antinatriuresis after intrarenal NOSI may be reversed, with consequent natriuresis, when MAP rises markedly, mainly because of a "pressure natriuresis" mechanism. 2, 8, 15, 16 Finally, these latter rat studies 16 also showed that ET receptor blockade was highly effective in preventing just the RPP-dependent portion of renal vasoconstriction during acute systemic NOSI. However, with our experimental design, a slight but significant change in MAP took place only after Ն45 minutes of L-NAME infusion. Thus, any confounding, unspecific effect of a marked increase in RPP on the L-NAME-induced renal changes should be minimized.
Available evidence from dog and human observations indicates that the vasoconstrictor action of ET in both systemic and renal circulation is mediated predominantly by ET A receptors. Studies by Verhaar et al 10 showed that local infusion of an ET A blocker in the forearm produced marked vasodilation, whereas ET B blockade led to only modest vasoconstriction. In the same human model, simultaneous ET A and ET B blockade was followed by vasodilation of a magnitude only slightly diminished with respect to ET A blockade alone. 10 Because forearm vasodilation secondary to ET A blockade was almost completely abolished by simultaneous NOSI with L-NMMA, 10 the contribution of endogenous ET to the baseline systemic vascular tone in equilibrium with tonic NO production appears to be mediated principally by ET A receptors. A similar vasodilatory action of ET A blockade was found in dog kidney, with a substantial increase in RBF in the absence of significant changes in MAP. 12 In addition, ET A blocking agents, even at doses devoid of systemic and renal vasodilatory effects, largely prevented renal vasoconstriction due to systemic infusion of ET-1 in conscious dog 17 and in humans. 13 Finally, infusion of the selective ET B receptor agonist ET3 did not affect kidney function of healthy humans. 18 In the present experiments, a very low infusion rate (0.125 nmol ⅐ kg Ϫ1 ⅐ min
Ϫ1
) of the specific peptide ET A receptor blocker BQ-123 was used. Previous studies in humans indicated that such an inhibitor produces systemic and renal vasodilation and a fall in MAP when infused at a rate up to 3 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 in heart failure 19 or hepatorenal 20 patients. These pathophysiological conditions, however, are potentially characterized by abnormally elevated activity of the ET system. 6 Conversely, BQ-123, when infused systemically in healthy subjects at rates ranging from 0.3 to 2.5 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 , did not exert any systemic or renal hemodynamic action. 13 However, it was able to vasodilate forearm when infused locally, 10 and, more Effects of infusion of 0.125 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 L-NAME and L-NAME plus BQ-123 in 8 Na-repleted healthy subjects on MAP, GFR, RBF, and RVR.
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importantly, to prevent renal vasoconstriction when coinfused systemically with ET-1. 13 In agreement with previous reports in healthy humans, 13 baseline MAP, renal hemodynamics, and cation excretion were not affected by BQ-123 infusion alone. Infusion of L-NAME resulted, as expected, in significant changes in basal renal hemodynamics and tubular reabsorption, with vasoconstriction, reduction in GFR, and fall in both absolute and fractional excretion of Li and Na. Both MAP and FF rose slightly after only 45 minutes of L-NAME infusion. These findings are consistent with previous animal and human investigations, including our recent studies performed with the same L-NAME infusion technique. 3, 14 During coinfusion of L-NAME and BQ-123, UNO x V fell to the same extent as during L-NAME alone, which indicates that the different magnitude of renal changes between the 2 infusions was not due to variations in the degree of NOSI, at least up to the limits of UNO x V as an approximate marker of whole body and, presumably, renal metabolism of NO. 3, 14 As the main finding from the present study, changes in ERPF, RBF, and RVR due to L-NAME were markedly attenuated when BQ-123 was simultaneously coinfused. The drop in GFR also showed a trend to be prevented by BQ-123, although without statistical significance. Finally, the increases in MAP and FF, both observed in the later period of L-NAME infusion, were abrogated.
These results point to a physiological interaction between ET A receptor activity and NO in the control of baseline vascular tone, not only in systemic circulation 2,10,11 but also in renal circulation. The inhibitory action of BQ-123 on increased MAP is in keeping with previous studies 21 showing that the marginal effect of ET receptor blockers on baseline MAP is markedly enhanced by NOSI. Our data therefore confirm a potential role of such drugs in treating hypertension in NO-deficient states. 22 Because BQ-123 not only attenuated the overall decrease in RBF and increase in RVR but also prevented the late rise in FF, the effect of ET A seemed to be focused on both arteriolar sides of the glomerulus. One could assume, however, that the modest increase in FF we observed in our human model was related to the slight but definite elevation in MAP, as suggested in rat kidney. 8, 15, 16 Thus, a specific interaction between ET and NO in the kidney should take place at the level of the afferent arteriole.
Several observations in chronically instrumented conscious rat 15 and healthy humans 3 showed no significant effects of blockade of the renin-angiotensin system on renal changes secondary to acute NOSI. This indicates that at least under baseline, unstimulated conditions of minimal Ang II concentration in the kidney, there are no interactions between NO and Ang II in controlling baseline renal hemodynamics. These latter results eliminate the possibility that the relationship between ET and NO we show here was mediated indirectly via a synergistic interaction between ET and Ang II. 23, 24 Recent studies in dogs indicated that ET A blockade may lead to an increase in renin production. 25 This effect took place, however, only when RPP was lowered, which suggests an enhanced sensitivity of the renin-angiotensin system to the changes in RPP secondary to ET A blockade. 25 Because MAP was kept constant or was increased modestly rather than decreased in our experiments, any interference by a possibly activated intrarenal renin-angiotensin system seems to be unlikely.
It is also known that NO has a distinct inhibitory effect on both synthesis and release of ET. 9, 26 The hypothesis may therefore be advanced that the interaction between NO and ET A receptor activity observed in the present study is not the expression of a balance between baseline endogenous NO and ET but rather of an increased ET production due to NOSI alone. The degree of NOSI-induced increase in circulating ET-1 has been shown to range from 0% to 20% in human studies, associated with a 5% to 7% increase in MAP, 4, 27 and from 40% to 70% in rat experiments, 25, 28 in which MAP rose by Ն20% to 30%. Such changes in circulating ET-1 are much smaller than those that occur after anesthesia in rats, 29 and they are in any case still below the vasoconstrictor threshold both in vitro 30 and in vivo, as indicated for systemic and renal circulation in studies in humans undergoing ET-1 infusion. 18, 31 We did not measure plasma ET-1 in this study, first because the above-reported evidence suggests that under our experimental conditions, significant variations in plasma ET-1 are very unlikely. In addition, plasma ET-1 may not reflect an increase in its tissue concentration due to an accentuated release of peptide on the basolateral side of endothelial cells. 6, 27 Thus, although the participation of relatively enhanced ET production in the kidney in response to NOSI cannot be excluded, such an effect should be minimized because of low doses of infused L-NAME and only modest, slow changes in MAP.
Coinfusion of BQ-123 did not affect Na and Li retention due to L-NAME, which indicates that at least under our experimental conditions, ET A blockade is unable to reverse the increased tubular reabsorption at both the proximal and postproximal level secondary to NOSI. It is generally believed that Na retention produced by infusion of ET-1 in both animals and humans results merely from renal vasoconstriction secondary to ET A receptor activation. 17, 18 Because low doses of ET-1 may be natriuretic in animals via activation of ET B receptors, 6, 7 it is conceivable that ET A receptor blockade unmasks an ET B -dependent natriuresis. However, BQ-123 did not affect either baseline Li or Na excretion or their increased reabsorption during L-NAME infusion. This latter finding was expected because ET B -mediated effects of ET on tubular reabsorption of both Na (inhibition) and water (stimulation) are dependent on NO synthesis, 6 which was in turn inhibited by L-NAME.
Because the physiological role of ET as a potent, endogenous vasoactive substance has been established, a number of peptide and nonpeptide ET receptor antagonists have been introduced for research and clinical purposes, 22, 27 pointing to a potential role of these drugs in both cardiovascular and renal disease. 22 An impairment in NO-dependent vascular function is a common finding in many cardiovascular diseases, including hypertension and heart failure. 11, 32 The present findings corroborate the view that ET A receptor blockade is a useful tool in preventing the endogenous ET-dependent component of systemic and renal vasoconstriction secondary to NO deficiency.
In summary, this study supports the concept that baseline ET A receptor activity exerts in humans a physiological interaction with endogenous NO, thus participating in the tonic control of systemic and renal hemodynamics. Such an interaction might also be important from a therapeutic point of view under clinical conditions of impaired NO availability in both systemic and renal vasculature.
